secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001802768-25-000113
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q3 Portfolio Receipts +11% to $814M; raises FY guidance to $3,200-$3,250M
--------------------------------------------------------------------------------

- Portfolio Receipts $814M (+11% YoY); Royalty Receipts $811M (+11%). Net cash ops $703M.
- Raised FY 2025 guidance: Portfolio Receipts now $3,200-$3,250M (14-16% growth, previously $3,050-$3,150M).
- Adjusted EBITDA $779M, Portfolio Cash Flow $657M. Capital Deployment $1.0B in Q3 (Imdelltra, obexelimab, Amvuttra).
- Repurchased 4M shares for $152M in Q3; $1.2B YTD share repurchases.
- Issued $2B senior notes at 5.16% in Sep; repaid $1B notes in Aug; total debt $9.2B at 3.75% avg cost.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000180276825000113/0001802768-25-000113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000180276825000113/rprx-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001802768-25-000113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer